Profile data is unavailable for this security.
About the company
Arcellx, Inc. is a clinical-stage biotechnology company. The Company is focused on the development of controllable cell therapies for the treatment of patients with cancer and other incurable diseases. The Company’s lead program is a BCMA-targeting ddCAR product candidate called CART-ddBCMA, which is being evaluated in its pivotal Phase II iMMagine-1 trial in patients with relapsed or refractory multiple myeloma (rrMM). The Company is also developing two clinical-stage ARC-SparX programs in Phase I trials; ACLX-001, which targets BCMA in rrMM, and ACLX-002, which targets CD123 in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Outside of multiple myeloma (MM), the Company advances its wholly owned portfolio of clinical-stage, ACLX-002, and preclinical pipeline programs incorporating its D-Domain technology. D-Domain, is designed to overcome the limitations of traditional Chimeric Antigen Receptor T-cells (CAR-Ts).
- Revenue in USD (TTM)131.66m
- Net income in USD-50.54m
- Incorporated2014
- Employees130.00
- LocationArcellx Inc800 Bridge ParkwayREDWOOD CITY 94065United StatesUSA
- Phone+1 (240) 327-0603
- Fax+1 (302) 655-5049
- Websitehttps://www.arcellx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MoonLake Immunotherapeutics | 0.00 | -40.68m | 2.85bn | 50.00 | -- | 5.18 | -- | -- | -0.7501 | -0.7501 | 0.00 | 8.63 | 0.00 | -- | -- | 0.00 | -14.53 | -- | -15.60 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.93bn | 91.00 | -- | 3.53 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| ACADIA Pharmaceuticals Inc | 813.81m | -1.71m | 3.00bn | 610.00 | -- | 6.44 | 334.91 | 3.68 | -0.0129 | -0.0129 | 4.93 | 2.81 | 1.08 | 1.85 | 10.13 | 1,363,159.00 | -0.2264 | -27.50 | -0.3579 | -32.73 | 92.27 | 95.62 | -0.2101 | -38.35 | 1.86 | -- | 0.00 | -- | 40.45 | 26.55 | 71.62 | -- | 79.52 | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 3.04bn | 226.00 | -- | 49.28 | -- | 33.02 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Amicus Therapeutics, Inc. | 423.49m | -147.07m | 3.04bn | 517.00 | -- | 23.30 | -- | 7.19 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| Azenta Inc | 651.76m | -152.26m | 3.11bn | 3.40k | -- | 1.42 | -- | 4.78 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| TG Therapeutics Inc | 289.33m | 41.20m | 3.16bn | 284.00 | 92.70 | 19.73 | 76.36 | 10.92 | 0.2205 | 0.2205 | 1.97 | 1.04 | 1.01 | 0.3567 | 7.86 | 1,095,962.00 | 14.44 | -62.87 | 20.20 | -80.06 | 93.53 | -- | 14.24 | -405.03 | 2.84 | 4.01 | 0.3876 | -- | 8,290.02 | 333.86 | 106.39 | -- | -- | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.22bn | 239.00 | -- | 9.89 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 3.25bn | 251.00 | -- | 3.67 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Denali Therapeutics Inc | 295.39m | -137.25m | 3.36bn | 375.00 | -- | 2.30 | -- | 11.36 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Arcellx Inc | 131.66m | -50.54m | 3.37bn | 130.00 | -- | 6.76 | -- | 25.59 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 3.55bn | 124.00 | -- | 3.42 | -- | 229.14 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 3.57bn | 525.00 | -- | 7.38 | -- | 100.66 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Alvotech SA | 114.39m | -494.28m | 3.62bn | 999.00 | -- | -- | -- | 31.67 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
Data as of Jul 23 2024. Currency figures normalised to Arcellx Inc's reporting currency: US Dollar USD
47.98%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 4.98m | 9.30% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 3.93m | 7.35% |
| Paradigm BioCapital Advisors LPas of 31 Mar 2024 | 3.82m | 7.14% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.75m | 5.14% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 2.13m | 3.98% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.89m | 3.52% |
| Cormorant Asset Management LPas of 31 Mar 2024 | 1.78m | 3.33% |
| Suvretta Capital Management LLCas of 31 Mar 2024 | 1.56m | 2.92% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 1.51m | 2.82% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.32m | 2.47% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
